News

Funding Opportunities for biotech in the fight against COVID-19

Find our overview of funding opportunities for research & innovation in the fight against COVID-19.

European Reasearch Area (ERA) Corona Platform

 

EU Solidarity Fund

 

 
European Investment Fund
 
 
Innovative Medicines Initiative (IMI)
 
 
 
 

 

InnovFin 
 
 
 
 
 
 
 
 
Coalition for Epidemic Preparedness Innovation (CEPI)
 
BSAC COVID-19 
 
LifeArc
 
 
 
 
 
H2020 - Epidemics-EICPrize-2020
 

 

 

Wellcome Trust
 

 

 

Bill & Melinda Gates Foundation
 

 

 

European vaccine infrastructure TRANSVAC2

 

 

 

Elrha 

 

 

 

ESCALAR

    Find regualrly updated information on research & innovation pogrammes, inclduing FAQs on Horizon 2020 calls and grants & updated info on extension of call deadlines. Find out more

    In response to the COVID-19 outbreak and the urgency to address the associated public health crisis, the scope of the European Union Solidarity Fund (EUSF) has been extended to encompass major public health emergencies. Find out more

    The EIF and European Commission are launching specific COVID-19 support under the COSME Loan Guarantee Facility (COSME LGF), which is supported by the The European Fund for Strategic Investments (EFSI). Find out more

    Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the following objectives: development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak; development of therapeutics to address the current and/or future coronavirus outbreaks; development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies; or development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection. Find our more
     
    InnovFin Infectious Diseases is a joint initiative by the European Investment Bank (EIB) and the European Commission under Horizon 2020, providing funding for the development of vaccines, drugs, medical and diagnostic devices, and research infrastructures for combatting infectious diseases. The funding is aimed at projects that have passed the pre-clinical stage and for which clinical validation is needed for further development. Find out more

    Under the scheme InnovFin SME Guarantee Facility the EIF will be able to provide enhanced terms and conditions for guarantees and counter-guarantees to incentivize financial intermediaries to provide working capital financing to European SMEs and mid-caps hit by the economic impact of the coronavirus pandemic. Find out more

    CEPI funding facilitates the development of vaccines against those emerging infectious diseases (EIDs) for which the usual commercial incentives for development are inadequate. A strategic objective of CEPI is to advance the development of technology platforms that enable a rapid response to protect at-risk populations against EIDs. Find out more

    A COVID-19 funding call to support researchers in microbiology in better understanding and addressing COVID-19 outbreak. Find out more

    LifeArc is a UK-registered and self-funded charity that aims to drive medical innovation through their own research as well as through their work with a range of partners from industry, charities, universities, research organizations and others involved in improving lives for patients. Find out more

    The challenge is to develop a reliable, cost-effective and scalable early warning system prototype to forecast and monitor vector-borne diseases, which should encompass innovative technological solutions integrating big data derived from different sources (e.g. space-borne, airborne, in-situ and citizen observations) in Earth observation domain, including climate data, vector-related modelling, meteorology, and geo-located information related to vector-borne disease outbreaks and behaviour. These should be interoperable with public health data and other socio-economic data. The solution must be a fully functional prototype system. Find out more

    This call aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity. Find out more

    The Bill and Melinda Gates Foundation is joining forces with Wellcome and Mastercard. They have announced to invest $125 million to tackle COVID-19. The money will be used to identify potential treatments for COVID-19, accelerate their development, and prepare for the manufacture of millions of doses for use worldwide. The expertise of biotech companies will be critical to this endeavor, named the COVID-19 Therapeutics Accelerator. Find out more

    In order to support the fight against COVID-19, the European vaccine infrastructure TRANSVAC2, is encouraging researchers working on COVID19 to apply for the high-quality technical vaccine development services offered by their infrastructure. With a few exceptions, services are free-of-charge. Some of the services COVID-19 researchers may benefit from are: Animal models, Adjuvant formulation , Clinical trial support and Regulatory support. Find out more

    Elrha is launching an urgent funding call for research proposals to support the COVID-19 response in humanitarian settings. The call aims to fund public health research that will produce robust findings that will contribute to the effectiveness of the current humanitarian response and increase the evidence base for future responses to similar infectious disease outbreaks. Find out more

    ESCALAR, a new investment approach, developed by the European Commission together with the European Investment Fund (EIF), will support venture capital and growth financing for promising companies, enabling them to scale up in Europe and help reinforce Europe’s economic and technological sovereignty. It will provide up to €300 million aiming to increase the investment capacity of venture capital and private equity funds, triggering investments of up to €1.2 billion, or four times the original investment, to support promising companies.Find out more